6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $201M | -$67M | 51.8% | -20.0% | -$9M | — | $91M |
| 2024 | $200M | -$6M | 55.4% | -10.2% | $22M | — | $99M |
| 2023 | $193M | -$12M | 56.7% | -14.4% | $633000 | — | $167M |
| 2022 | $164M | $2M | 61.6% | -1.1% | -$22M | — | $297M |
| 2021 | $128M | $3M | 61.9% | 7.2% | $266000 | — | $365M |
| 2020 | $93M | $19M | 55.7% | 14.7% | $14M | — | $165M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $44M | -$19M | 48.2% | -41.8% | -$5M | — | $66M |
| Dec '25 | $62M | — | 52.9% | -9.0% | -$2M | — | $91M |
| Sep '25 | $52M | — | 52.7% | -17.6% | -$5M | — | $93M |
| Jun '25 | $46M | — | 52.3% | -23.3% | -$1M | — | $75M |
| Mar '25 | $41M | -$11M | 48.6% | -36.1% | -$974000 | — | $95M |
| Dec '24 | $57M | — | 58.5% | 5.2% | $1M | — | $99M |
| Sep '24 | $52M | — | 56.3% | -8.2% | $12M | — | $162M |
| Jun '24 | $47M | — | 54.6% | -18.3% | $5M | — | $178M |
| Mar '24 | $45M | -$6M | 51.3% | -23.9% | $3M | — | $169M |
| Dec '23 | $58M | — | 56.8% | -0.2% | $8M | — | $167M |
| Sep '23 | $48M | — | 56.6% | -13.4% | -$6M | — | $164M |
| Jun '23 | $50M | -$4M | 56.7% | -18.4% | -$4M | — | $132M |
| Mar '23 | $37M | -$7M | 56.7% | -32.8% | $2M | — | $129M |
| Dec '22 | $48M | $4M | 60.8% | 0.2% | -$337000 | — | $297M |
| Sep '22 | $40M | $2M | 66.4% | 3.4% | -$9M | — | $342M |
| Jun '22 | $40M | -$702000 | 61.2% | -2.2% | -$11M | — | $350M |
| Mar '22 | $35M | -$2M | 57.5% | -6.7% | -$2M | — | $363M |
| Dec '21 | $39M | -$1M | 60.8% | 3.4% | $4M | — | $365M |
| Sep '21 | $34M | $1M | 61.9% | 8.4% | -$147000 | — | $377M |
| Jun '21 | $30M | $3M | 64.9% | 12.5% | -$5M | — | $160M |
How the market has priced CTKB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cytek Biosciences, Inc.'s revenue has grown 16.8% per year. These are computed facts, not advice.
As of FY2025, Cytek Biosciences, Inc. reported — of total debt against $91M of cash; operating income covered interest expense -85.2×.
In FY2025, gross margin was 51.8%, operating margin -20.0%, and net margin -33.0%.
As of Jun '26, Cytek Biosciences, Inc. traded at a price-to-earnings ratio of about 474.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.